Guardion
An LN₂-free, cryopreservation system engineered for precision, speed and ease of use, from the lab, through to commercialisation.

Vitrafy is a cryopreservation technology company delivering solutions for human and animal health.
vitrafy.comCrawled Nov 20, 2026
An LN₂-free, cryopreservation system engineered for precision, speed and ease of use, from the lab, through to commercialisation.
Builds and adapts cryopreservation workflowsto improve process control.
Vitrafy’s integrated platform enables biomaterial preservation, end-to-end traceability, and real-time operational insights through unified data.
Sample-specific cryopreservation preserves whole blood with high post-thaw viability, overcoming conventional storage limitations.
Controlled cryopreservation extends platelet shelf life, reduces wastage, and delivers high-quality cryopreserved platelets to stabilize supply.
Brent Owens, Co-Founder and Executive Director shares how Vitrafy’s groundbreaking cryopreservation technology is helping to transform global health outcomes
Advanced cryogenic packaging and controlled heat-transfer technologies improve post-thaw viability in cryopreservation.
Vitrafy is a team of engineers, scientists, and innovators dedicated to solving the most critical challenges in cryopreservation with technology that makes a
Advanced software and controlled freezing that preserves biomaterial value, enhances reproducibility, and streamlines cryopreservation workflows at scale.
Vitrafy Life Sciences highlights advancements in its blood-based diagnostic platform at the Bell Potter Healthcare Conference. The company emphasizes accelerating progress in blood sample processing and analysis, targeting faster clinical insights. Vitrafy’s technology focuses on liquid biopsy applications, aiming to improve early disease detection.
Vitrafy Life Sciences expands its U.S. blood collection network by acquiring Versiti and Charter Medical, now covering **17% of civilian blood collection sites** in the country. The move strengthens its position in plasma and blood product sourcing. The company operates in the healthcare sector, specializing in plasma collection and processing.
Versiti partners with Vitrafy Life Sciences to assess Vitrafy’s advanced cryopreservation technology, initially targeting platelet storage. The collaboration aims to test whether the technology preserves blood product viability beyond current methods. Both companies specialize in blood banking and life sciences innovation.
Vitrafy Life Sciences is forming partnerships with US blood centres to integrate its blood preservation technology. The company develops solutions aimed at extending the shelf life of stored blood products. These collaborations focus on scaling adoption of its proprietary preservation methods in clinical settings.
Vitrafy Life Sciences Limited expands its presence in the US blood market by partnering with the Hoxworth Blood Center. The collaboration aims to strengthen Vitrafy’s distribution and operational capabilities within the blood services sector. The company continues to grow its footprint in North America through strategic alliances.
Vitrafy Life Sciences secures $30 million in funding to expand its operations in the United States and scale production of its Guardion product line. The company focuses on advanced materials for medical and industrial applications, leveraging its proprietary technology to enhance performance and safety in critical sectors.